Success Metrics

Clinical Success Rate
85.2%

Based on 23 completed trials

Completion Rate
85%(23/27)
Active Trials
4(11%)
Results Posted
61%(14 trials)
Terminated
4(11%)

Phase Distribution

Ph phase_1
3
8%
Ph not_applicable
2
6%
Ph phase_4
8
22%
Ph early_phase_1
2
6%
Ph phase_2
13
36%
Ph phase_3
6
17%

Phase Distribution

5

Early Stage

13

Mid Stage

14

Late Stage

Phase Distribution34 total trials
Early Phase 1First-in-human
2(5.9%)
Phase 1Safety & dosage
3(8.8%)
Phase 2Efficacy & side effects
13(38.2%)
Phase 3Large-scale testing
6(17.6%)
Phase 4Post-market surveillance
8(23.5%)
N/ANon-phased studies
2(5.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.2%

23 of 27 finished

Non-Completion Rate

14.8%

4 ended early

Currently Active

4

trials recruiting

Total Trials

36

all time

Status Distribution
Active(4)
Completed(23)
Terminated(4)
Other(5)

Detailed Status

Completed23
unknown5
Terminated4
Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
36
Active
4
Success Rate
85.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (5.9%)
Phase 13 (8.8%)
Phase 213 (38.2%)
Phase 36 (17.6%)
Phase 48 (23.5%)
N/A2 (5.9%)

Trials by Status

terminated411%
completed2364%
recruiting411%
unknown514%

Recent Activity

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more
NCT07101445Phase 4

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Recruiting
NCT05421416Phase 2

Loratadine for the Prevention of G-CSF-related Bone Pain

Recruiting
NCT07300735Not Applicable

Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers

Recruiting
NCT06019728Phase 4

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

Completed
NCT06955741Phase 1

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

Completed
NCT06531707Phase 3

Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine

Recruiting
NCT05043350Phase 2

Combined Antihistaminics Therapy in COVID 19 Patients

Completed
NCT04211259Early Phase 1

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Unknown
NCT05750875Phase 4

Gabapentin Versus Loratadine in Uremic Pruritus

Completed
NCT04248712Phase 2

Antihistamines in Eosinophilic Esophagitis

Terminated
NCT02495077Phase 2

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Completed
NCT05243706Phase 3

Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy

Unknown
NCT03855228Phase 3

Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)

Completed
NCT05190627Phase 2

Effect of Loratadine in Lymphangioleiomyomatosis

Unknown
NCT02583594Phase 1

A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

Completed
NCT03883386Phase 2

Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use

Terminated
NCT02478398Phase 3

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Completed
NCT02392039Early Phase 1

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

Terminated
NCT02339714Phase 2

Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis

Completed
NCT02305979

Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies

Completed

Drug Details

Intervention Type
DRUG
Total Trials
36